Request a copy

Full Text

• Van Staa, T.P., Leufkens, H.G.M., Abenhaim, L., Begaud, B., Zhang, B., Cooper, C., Use of oral corticosteroids in the United Kingdom (2000) Q Med J, 93, pp. 105-111
• Canalis, E., Bilezekian, J.P., Angeli, A., Giustina, A., Perspectives on glucocorticoid-induced osteoporosis (2004) Bone, 34, pp. 593-598
• Van Staa, T.P., Leufkens, H.G.M., Cooper, C., A meta-analysis of the epidemiology of corticosteroid-induced osteoporosis (2002) Osteoporos Int, 13, pp. 777-787
• Van Staa, T.P., Leufkens, H.G.M., Abenhaim, L., Zhang, B., Cooper, C., Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses (2000) Rheumatol, 39, pp. 1383-1389
• Van Staa, T., Leufkens, H.G.M., Abenhaim, L., Zhang, B., Cooper, C., Use of oral corticosteroids and risk of fractures (2000) J Bone Miner Res, 15, pp. 993-1000
• Rfjm, L., Riel Plcm, V., Van De Putte, L.B.A., Erning Ljto, V., Van'T Hof, M.A., Lemmens, J.A.M., Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid-arthritis - A randomized, controlled-study (1993) Ann Intern Med, 119, pp. 963-968
• Kanis, J.A., Johansson, H., Oden, A., A meta-analysis of prior corticosteroid use and fracture risk (2004) J Bone Miner Res, 19, pp. 893-899
• Luengo, M., Picado, C., Del Rio, L., Guanabens, N., Montserrat, J.M., Setoain, J., Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma (1990) Am Rev Resp Dis, 142, pp. 104-107
• Van Staa, T.P., Laan, R.F., Barton, I.P., Cohen, S., Reid, D.R., Cooper, C., Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy (2003) Arthritis Rheum, 48, pp. 3224-3229
• Dalle Carbonare, L., Arlot, M.E., Chavassieux, P.M., Roux, J.P., Portero, N.R., Meunier, P.J., Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis (2001) J Bone Miner Res, 16, pp. 97-103
• Bresssot, C., Meunier, P.J., Chapuy, M.C., Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis (1979) Metab Bone Dis Rel Res, 1, pp. 303-311
• Dempster, D.W., Bone histomorphometry in glucocorticoid-induced osteoporosis (1989) J Bone Miner Res, 4, pp. 137-147
• Dempster, D.W., Arlot, M.A., Meunier, P.J., Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis (1983) Calcif Tissue Int, 35, pp. 410-417
• Compston, J.E., Reginster, J.-Y., Avouac, B., Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis (1996) Calcif Tissue Int, 59, pp. 323-327
• Abadie, E.C., Devogelaer, J.-P., Ringe, J.D., Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: Updated recommendations from the Group for the Respect of Ethics and Excellence in Science (2005) Sem Arthritis Rheum, 35, pp. 1-4
• Saag, K.G., Emkey, R., Schnitzer, T.J., Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis (1998) New Engl J Med, 339, pp. 292-299
• Cohen, S., Levy, R.M., Keller, M., Risedronate therapy prevents corticosteroid-induced bone loss (1999) Arthritis Rheum, 42, pp. 2309-2318
• Reid, D.M., Hughes, R.A., Rfjm, L., Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomised trial (2000) J Bone Miner Res, 15, pp. 1006-1013
• Orwoll, E.S., Ettinger, M., Weiss, S., Alendronate for the treatment of osteoporosis in men (2000) New Engl J Med, 343, pp. 604-610
• Bobba, R., Adachi, J.D., Review of the safety and efficacy for the treatment of male osteoporosis (2007) Clin Interv Aging, 2, pp. 275-282
• Orwoll, E.S., Scheele, W.H., Paul, S., The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis (2003) J Bone Miner Res, 18, pp. 9-17